Banyu And Ono Apply For Additional Indication For Sitagliptin
This article was originally published in PharmAsia News
Executive Summary
Ono Pharmaceutical and Merck Japanese subsidiary Banyu submitted an application for sitagliptin use with an alpha-glucosidase inhibitor